Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer

Article

Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.

Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content
The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

Idylla CDx MSI Test Earns FDA Approval in MSI-H Colorectal Cancer

Roman Fabbricatore
September 16th 2025
Article
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 16th 2025
Podcast
Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.

How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

Tim Cortese
September 16th 2025
Article
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast
Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 16th 2025
Article
While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 16th 2025
Article